
Wieslaw Swietnicki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6871588/publications.pdf Version: 2024-02-01



WIESLAW SWIETNICK

#	Article	IF	CITATIONS
1	Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nature Structural Biology, 2001, 8, 770-774.	9.7	474
2	pH-dependent Stability and Conformation of the Recombinant Human Prion Protein PrP(90–231). Journal of Biological Chemistry, 1997, 272, 27517-27520.	3.4	239
3	Membrane Environment Alters the Conformational Structure of the Recombinant Human Prion Protein. Journal of Biological Chemistry, 1999, 274, 36859-36865.	3.4	230
4	Aggregation and Fibrillization of the Recombinant Human Prion Protein huPrP90â^'231. Biochemistry, 2000, 39, 424-431.	2.5	216
5	Familial Mutations and the Thermodynamic Stability of the Recombinant Human Prion Protein. Journal of Biological Chemistry, 1998, 273, 31048-31052.	3.4	176
6	The Prion Protein Has RNA Binding and Chaperoning Properties Characteristic of Nucleocapsid Protein NCp7 of HIV-1. Journal of Biological Chemistry, 2001, 276, 19301-19309.	3.4	163
7	Solution Structure of the E200K Variant of Human Prion Protein. Journal of Biological Chemistry, 2000, 275, 33650-33654.	3.4	120
8	The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein 1 1Edited by J. Karn. Journal of Molecular Biology, 2001, 307, 1011-1021.	4.2	118
9	Identification of an epitope in the C terminus of normal prion protein whose expression is modulated by binding events in the N terminus 1 1Edited by F. Cohen. Journal of Molecular Biology, 2000, 301, 567-573.	4.2	110
10	Hepatitis A virus 3C proteinase substrate specificity. Biochemistry, 1992, 31, 7862-7869.	2.5	75
11	Identification of Small-Molecule Inhibitors of Yersinia pestis Type III Secretion System YscN ATPase. PLoS ONE, 2011, 6, e19716.	2.5	64
12	Folding aggregated proteins into functionally active forms. Current Opinion in Biotechnology, 2006, 17, 367-372.	6.6	50
13	Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment. Oncology Reports, 2014, 32, 491-504.	2.6	41
14	Yersinia pestis Yop secretion protein F: Purification, characterization, and protective efficacy against bubonic plague. Protein Expression and Purification, 2005, 42, 166-172.	1.3	34
15	KBTBD13 interacts with Cullin 3 to form a functional ubiquitin ligase. Biochemical and Biophysical Research Communications, 2012, 421, 743-749.	2.1	34
16	Novel Protein-Protein Interactions of the Yersinia pestis Type III Secretion System Elucidated with a Matrix Analysis by Surface Plasmon Resonance and Mass Spectrometry. Journal of Biological Chemistry, 2004, 279, 38693-38700.	3.4	32
17	Review of Potential Pseudomonas Weaponry, Relevant to the Pseudomonas–Aspergillus Interplay, for the Mycology Community. Journal of Fungi (Basel, Switzerland), 2020, 6, 81.	3.5	32
18	PrPC has nucleic acid chaperoning properties similar to the nucleocapsid protein of HIV-1. Comptes Rendus - Biologies, 2002, 325, 17-23.	0.2	29

WIESLAW SWIETNICKI

#	Article	IF	CITATIONS
19	Thermodynamic Stabilization of the Folded Domain of Prion Protein Inhibits Prion Infection inÂVivo. Cell Reports, 2013, 4, 248-254.	6.4	28
20	A Yersinia pestisYscN ATPase mutant functions as a live attenuated vaccine against bubonic plague in mice. FEMS Microbiology Letters, 2012, 332, 113-121.	1.8	23
21	Analysis of Proteinase Specificity by Studies of Peptide Substrates: The Use of UV and Fluorescence Spectroscopy to Quantitate Rates of Enzymatic Cleavage. , 1994, 36, 225-244.		21
22	Zinc Binding and Dimerization of Streptococcus pyogenes Pyrogenic Exotoxin C Are Not Essential for T-cell Stimulation. Journal of Biological Chemistry, 2003, 278, 9885-9895.	3.4	20
23	Metallacarborane Derivatives Effective against Pseudomonas aeruginosa and Yersinia enterocolitica. International Journal of Molecular Sciences, 2021, 22, 6762.	4.1	17
24	Design of small molecule inhibitors of type III secretion system ATPase EscN from enteropathogenic Escherichia coli Acta Biochimica Polonica, 2017, 64, 49-63.	0.5	16
25	Identification of a potent inhibitor of type II secretion system from Pseudomonas aeruginosa. Biochemical and Biophysical Research Communications, 2019, 513, 688-693.	2.1	11
26	Yersinia pestis YopD 150–287 fragment is partially unfolded in the native state. Protein Expression and Purification, 2008, 58, 53-60.	1.3	7
27	Fv structure of monoclonal antibody II-481 against herpes simplex virus Fc gamma-binding glycoprotein gE contains immunodominant complementarity determining region epitopes that react with human immunoglobulin M rheumatoid factors Journal of Experimental Medicine, 1994, 180, 1873-1888.	8.5	5
28	Dihydrolipoamide Acetyltransferase AceF Influences the Type III Secretion System and Resistance to Oxidative Stresses through RsmY/Z in Pseudomonas aeruginosa. Microorganisms, 2022, 10, 666.	3.6	4
29	Identification of small molecule compounds active against Staphylococcus aureus and Proteus mirabilis. Biochemical and Biophysical Research Communications, 2018, 506, 1047-1051.	2.1	3
30	In silico analysis of bacteriophage tail tubular proteins suggests a putative sugar binding site and a catalytic mechanism. Journal of Molecular Graphics and Modelling, 2019, 92, 8-16.	2.4	2
31	Prediction of Selected Biosynthetic Pathways for the Lipopolysaccharide Components in Porphyromonas gingivalis. Pathogens, 2021, 10, 374.	2.8	1
32	Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens. Biomolecules, 2021, 11, 892.	4.0	1
33	Model systems to study a superantigen-induced disease: Toxic shock syndrome. Drug Discovery Today: Disease Models, 2006, 3, 121-126.	1.2	0